Switch theme
Sign up to access all valuation multiples
Shanghai Hile Bio-Technology Co Ltd is a veterinary biological product manufacturer integrating research and development, production, sales, and service. The company has over 40 categories of poultry, livestock, and pets. The company provides services for the prevention of livestock diseases, improving the health of livestock and poultry, and improving the production efficiency of farmers, and is able to provide comprehensive solutions and an authoritative veterinary expert service system.
1981
n/a
LTM Revenue n/a
LTM EBITDA n/a
$679M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shanghai Hile Bio-Tech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Shanghai Hile Bio-Tech achieved revenue of $33.2M and an EBITDA of $13.9M.
Shanghai Hile Bio-Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shanghai Hile Bio-Tech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $33.2M | n/a | XXX | XXX | XXX |
| Gross Profit | $26.7M | $24.4M | XXX | XXX | XXX |
| Gross Margin | 80% | NaN% | XXX | XXX | XXX |
| EBITDA | $13.9M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 42% | NaN% | XXX | XXX | XXX |
| Net Profit | $7.4M | $16.8M | XXX | XXX | XXX |
| Net Margin | 22% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Shanghai Hile Bio-Tech's stock price is CNY 8 (or $1).
Shanghai Hile Bio-Tech has current market cap of CNY 5.1B (or $701M), and EV of CNY 4.9B (or $679M).
See Shanghai Hile Bio-Tech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $679M | $701M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Shanghai Hile Bio-Tech has market cap of $701M and EV of $679M.
Shanghai Hile Bio-Tech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Shanghai Hile Bio-Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Shanghai Hile Bio-Tech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $679M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpShanghai Hile Bio-Tech's NTM/LTM revenue growth is n/a
Shanghai Hile Bio-Tech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Shanghai Hile Bio-Tech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Shanghai Hile Bio-Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Shanghai Hile Bio-Tech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 49% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai Hile Bio-Tech acquired XXX companies to date.
Last acquisition by Shanghai Hile Bio-Tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai Hile Bio-Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Shanghai Hile Bio-Tech founded? | Shanghai Hile Bio-Tech was founded in 1981. |
| Where is Shanghai Hile Bio-Tech headquartered? | Shanghai Hile Bio-Tech is headquartered in China. |
| Is Shanghai Hile Bio-Tech publicy listed? | Yes, Shanghai Hile Bio-Tech is a public company listed on SHG. |
| What is the stock symbol of Shanghai Hile Bio-Tech? | Shanghai Hile Bio-Tech trades under 603718 ticker. |
| When did Shanghai Hile Bio-Tech go public? | Shanghai Hile Bio-Tech went public in 2015. |
| Who are competitors of Shanghai Hile Bio-Tech? | Similar companies to Shanghai Hile Bio-Tech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Shanghai Hile Bio-Tech? | Shanghai Hile Bio-Tech's current market cap is $701M |
| Is Shanghai Hile Bio-Tech profitable? | Yes, Shanghai Hile Bio-Tech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
